Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the esophageal cancer drug market in India will grow from $16 million in 2009 to $36 million in 2014. This growth will be fueled by improved access to medical care, a growing drug-treated population and a rising number of higher-income, brand-conscious esophageal cancer patients driving the demand for more efficacious drugs.
The new Emerging Markets report entitled Esophageal Cancer in India finds that in 2009, multinational corporations accounted for 44 percent of total sales in the esophageal cancer market in India and will command 42 percent of sales by 2014. Uptake of high-price targeted therapies will increase and will offset competition from less-expensive Indian brands/generics.
"The use of targeted therapies such as, Merck KGaA's Erbitux and Roche's Herceptin, to treat esophageal cancer in India will increase as more results from clinical studies become available during our 2009 - 2014 forecast period. According to surveyed Indian oncologists however, an off-label market for these therapies -- which are approved for other cancers in India -- already exists. Most importantly neither of these drugs competes with a generic in India," stated Decision Resources' Vice President of Emerging Markets Kate Hohenberg.
The report also finds that treatment modalities for esophageal cancer are generally similar in the four key regions of India (Delhi, Mumbai, Bangalore/Chennai and Kolkata/Hyderabad/Jaipur/Lucknow). Oncologists from Bangalore/Chennai, however are more conservative about treating recurrent esophageal cancer with chemotherapy. In contrast to their colleagues in the other major cities, they tend to perform more surgery and radiation to ease the symptoms.
The report contains primary research of physicians and epidemiology in key pharmaceutical markets of India -- Delhi, Mumbai, Bangalore/Chennai and Kolkata/Hyderabad/Jaipur/Lucknow.
About Emerging Markets Reports
Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Christopher Comfort Decision Resources, Inc. 781-296-2597 email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Christopher Comfort of Decision Resources, Inc.,
Web Site: http://www.decisionresources.com/